Because less than 50% of tumor cells are CD117-positive in some cases of GIST, the use of melanocytic markers is mandatory because GISTs are negative for melanocytic markers.[34] Immunohistochemical demonstration of melanocytic differentiation is the most reliable way to distinguish PEComa from GIST. Here, KIT is linked to neoplasm with perivascular epithelioid cell differentiation.